Inactief instrument

Andere talen ITUS Corp Nasdaq

Aandelen

US45069V2034

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines	08/05
Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	08/05
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja	06/05
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 and 9, 2024	01/05
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024	30/04
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board	19/04
Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	18/04
InvestorBrandMedia: Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth	20/03
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties	14/03
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	12/03
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress	11/03
Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment	12/02
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial	12/02
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference	29/01
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology	24/01
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	23/01
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	23/01
North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	23/01
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	16/01
North American Morning Briefing : Stock Futures -2-	16/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ITUS Corp Nasdaq

Aandelen

US45069V2034

Andere talen

Filters